PMID- 28088584
OWN - NLM
STAT- MEDLINE
DCOM- 20180402
LR  - 20180412
IS  - 1096-3650 (Electronic)
IS  - 1044-579X (Linking)
VI  - 43
DP  - 2017 Apr
TI  - Proton pump inhibition and cancer therapeutics: A specific tumor targeting or it 
      is a phenomenon secondary to a systemic buffering?
PG  - 111-118
LID - S1044-579X(17)30003-2 [pii]
LID - 10.1016/j.semcancer.2017.01.003 [doi]
AB  - One of the unsolved mysteries in oncology includes the strategies that cancer 
      cells adopt to cope with an adverse microenvironment. However, we knew, from the 
      Warburg's discovery that through their metabolism based on sugar fermentation, 
      cancer cells acidify their microenvironment and this progressive acidification 
      induces a selective pressure, leading to the development of very malignant cells 
      entirely armed to survive in the hostile microenvironment generated by their own 
      metabolism. In the last decades a primordial role for proton exchangers has been 
      supported as a key tumor advantage in facing off the acidic milieu. Proton 
      exchangers do not allow intracellular acidification through a continuous 
      elimination of H+ either outside the cells or within the internal vacuoles. This 
      article wants to comment a translational process through that led to the 
      preclinical demonstration that a class of proton pump inhibitors (PPI) exploited 
      worldwide for peptic ulcer treatment and gastroprotection are indeed powerful 
      chemosensitizers as well. In this process we achieved the clinical proof of 
      concept that PPI may well be included in new anti-cancer strategies with a solid 
      background and rationale.
CI  - Copyright (c) 2017 Elsevier Ltd. All rights reserved.
FAU - Spugnini, Enrico
AU  - Spugnini E
AD  - SAFU, Regina Elena Cancer Institute, Via Chianesi 53, 00134 Rome, Italy.
FAU - Fais, Stefano
AU  - Fais S
AD  - Dept. of Therapeutic Research and Medicines Evaluation Istituto Superiore di 
      Sanita (National Institute of Health), Viale Regina Elena 299, Rome Italy. 
      Electronic address: stefano.fais@iss.it.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20170111
PL  - England
TA  - Semin Cancer Biol
JT  - Seminars in cancer biology
JID - 9010218
RN  - 0 (Buffers)
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
MH  - Buffers
MH  - Humans
MH  - Neoplasms/*metabolism/pathology
MH  - Proton Pump Inhibitors/*administration & dosage
MH  - Tumor Microenvironment
OTO - NOTNLM
OT  - Chemosensitization
OT  - Lansoprazole
OT  - Pantoprazole
OT  - Proton pump inhibitors
OT  - Tumor acidity
EDAT- 2017/01/16 06:00
MHDA- 2018/04/03 06:00
CRDT- 2017/01/16 06:00
PHST- 2016/10/24 00:00 [received]
PHST- 2016/12/21 00:00 [revised]
PHST- 2017/01/06 00:00 [accepted]
PHST- 2017/01/16 06:00 [pubmed]
PHST- 2018/04/03 06:00 [medline]
PHST- 2017/01/16 06:00 [entrez]
AID - S1044-579X(17)30003-2 [pii]
AID - 10.1016/j.semcancer.2017.01.003 [doi]
PST - ppublish
SO  - Semin Cancer Biol. 2017 Apr;43:111-118. doi: 10.1016/j.semcancer.2017.01.003. 
      Epub 2017 Jan 11.